Navigation Links
Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company
Date:3/8/2011

BEVERLY, Mass., March 8, 2011 /PRNewswire/ -- Cellceutix Corporation (Pink Sheets: CTIX) today disclosed that it has entered into a Confidential Disclosure Agreement (CDA) pertaining to its anti-cancer drug, Kevetrin™, with one of the world's largest pharmaceutical companies.

Cellceutix CEO, Leo Ehrlich, commented, "It's relatively uncommon for big pharma to be signing a CDA on a compound before clinical trials are underway.  The process begins with Cellceutix providing non-confidential information to the other party.  If after review of the materials the interest remains high, they will request to enter into a CDA.   We are glad that their interpretation of the Kevetrin™ studies was sufficient to warrant entering into a CDA with Cellceutix."  Mr. Ehrlich continued, "Signing a CDA does not mean a licensing deal or other transaction is imminent and makes no assumptions that it ever will.  But, conversely, a deal won't ever happen without first signing a CDA.  At Cellceutix, we are focused on moving our compounds toward clinical trials and maximizing shareholders' value.  This agreement is one more step in that process."

Cellceutix has previously reported that in animal studies Kevetrin™ has shown potent anti-tumor activity against many different cancers including lung, breast and colon cancers as well as leukemia and various strains for which current drugs are ineffective ("drug-resistant cancers").  Data released over the last week by Cellceutix has also shown that Kevetrin™ demonstrates characteristics that are seen as highly desirable in a new chemotherapy as it has not only shown to be non-genotoxic, but also reactivates p53, the "Guardian Angel Protein."    

About Cellceutix

Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer.  Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, KM-133, for the treatment of psoriasis, and KM-391, for the treatment of autism.  More information is available on the Cellceutix web site at www.cellceutix.com.

Kevetrin, KM133, and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Cellceutix Corporation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.


'/>"/>
SOURCE Cellceutix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellceutix Discovers Drug Activates Guardian Angel p53 in Fight Against Leukemia
2. Cellceutix Cancer Drug Kevetrin™ Shows No Genotoxicity in Study
3. Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results
4. Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
5. RBC Life Sciences Reports Sales and Earnings Growth in 2010
6. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results
7. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
8. IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter
9. China Pharma Holdings, Inc. Reports Full Year 2010 Financial Results
10. Sequenom Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Assured Pharmacy Reports Same Store Sales for the Month of December 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 This report on the opioid induced ... of the global market. Large number of chronic pain ... constipation is a major side effect of consumption of ... targeted therapy has been prescribed to treat opioid induced ... medicines, and growing awareness about the therapy are the ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... Shire plc (LSE: SHP, NASDAQ: ... and Drug Administration (FDA) has acknowledged receipt of the ... for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. ... for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to ... the designated Prescription Drug User Fee Act (PDUFA) action ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... , ... “The Land of More and More”: a brilliant story for ... shares the simple and achievable answer. “The Land of More and More” is the ... Church in Angola, Indiana where he works with the children’s ministry department. , ...
(Date:1/19/2017)... ... ... Next week after January 20th, the fear for many is that the ... needs of over 30 million. Many interviews with Dr. Carol Francis at the Los ... were suppose to prioritize. Interviews provided below. , Among those present was ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... innovators, engineers, and scientists from around the world, announces the launch of its ... quick and easy portal to research breakthroughs and trending news, vital information on ...
(Date:1/19/2017)... Park City, Utah (PRWEB) , ... January 19, ... ... Sundance Film Festival in a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew ... Lounge to provide a condensed version of the clinic’s leading recovery program. ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... Conductor CTMS, which provides a modern CTMS workflow designed to seamlessly integrate and ... has been condensed to a single page, maximizing usability and improving efficiency significantly ...
Breaking Medicine News(10 mins):